ClinicalTrials.gg
CompletedNCT01868555Updated Oct 22, 2015

Safety, Pharmacokinetics and Pharmacodynamics of Two IDegAsp (One Explorative) Preparations and Two Insulin Degludec (One Explorative) Preparations in Japanese Subjects

A Phase 1 interventional study of insulin degludec and insulin degludec/insulin aspart 30 in Diabetes and Healthy, sponsored by Novo Nordisk A/S. Completed at 1 site in Japan. Open to male participants aged 20 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-10-22.

Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
20 Years to 45 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 103 studies testing insulin degludec in Diabetes Mellitus — 1 open to participants now, 1 under way, 1 of them phase 3. insulin degludec · Diabetes Mellitus.

Enrollment
77th of 103
32 · median 145
Started
2007
the only one that year
Phase 1
42 of 103
none open now
Registered
71st of 103
by date
Lead sponsor
96 of 103
Novo Nordisk A/S

Among the 103 studies testing insulin degludec in Diabetes Mellitus, this one is the 77th largest by enrollment, is the only one that started in 2007, is one of 42 in phase 1, and was the 71st registered.

Diabetes Mellitus

8,293 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

1 of the 103 studies testing insulin degludec in Diabetes Mellitus is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About insulin degludec

insulin degludec: first FDA approval 2015 (RYZODEG 70/30), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 648 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 195 (30%) stop at 75 or younger; 88 take children under 18; 182 take healthy volunteers.

This study: 20 Years to 45 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 103 studies testing insulin degludec in Diabetes Mellitus, or all of them as a file.
02

Study summary

This trial is conducted in Asia. The aim of this trial is to assess the safety, pharmacokinetics (the exposure of the trial drug in the body) and pharmacodynamics (the effect of the investigated drug on the body) of two insulin degludec/insulin aspart (IDegAsp) preparations and two insulin degludec (insulin 454) preparations in healthy Japanese male subjects. IDegAsp 45 (B) and insulin degludec (B) are explorative formulations, not similar to the proposed commercial formulations.

03

Conditions studied

  • Diabetes
  • Healthy

Browse trials for

04

Who can participate

Ages eligible
20 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy Japanese male subjects
  • (BMI) between 18.0 and 27.0 kg/m\^2 (both inclusive)
  • Body weight above or equal to 50 kg

Exclusion criteria

Exclusion Criteria:

  • The receipt of any drug within 16 weeks prior to this trial (the planned first dosing)
  • Any clinical laboratory values deviated from the reference range at the laboratory (except for cases within physiological change) or any abnormal (ECG) findings at the screening, as judged by the investigator or sub-investigator
  • Known or suspected allergy to trial product(s) or related products
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    IDegAsp 30

    Drug: insulin degludec/insulin aspart 30 · Drug: placebo

  • Experimental
    IDegAsp 45

    Drug: insulin degludec/insulin aspart 45 · Drug: placebo

  • Experimental
    insulin degludec (B)

    Drug: insulin degludec · Drug: placebo

  • Experimental
    insulin degludec (E)

    Drug: insulin degludec · Drug: placebo

Interventions

  • Administered as once daily subcutaneous (s.c., under the skin) dose per 0.6 nmol/kg body weight for 6 days

  • Druginsulin degludec/insulin aspart 30

    Administered as once daily subcutaneous (s.c., under the skin) dose per 0.6 nmol/kg body weight for 6 days

  • Druginsulin degludec/insulin aspart 45

    Administered as once daily subcutaneous (s.c., under the skin) dose per 0.6 nmol/kg body weight for 6 days

  • Drugplacebo

    Administered as once daily subcutaneous (s.c., under the skin) dose per 0.6 nmol/kg body weight for 6 days

06

What researchers measure

Primary outcomes

  1. Adverse events (AEs)

    Time frame: Day 1-6 and 7-28 days after day 6

Secondary outcomes

  1. Area under the serum insulin 454 concentration curve

    Time frame: 0-96 hours after last dosing

  2. Area under the serum insulin aspart concentration curve

    Time frame: 0-6 hours after dosing

07

Study locations

1 site
  • Tokyo, 1000005, Japan
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2007, a primary completion of Feb 2008 and a completion of Feb 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2013
First posted
Jun 4, 2013
Start
Dec 2007
Primary completionActual
Feb 2008
CompletionActual
Feb 2008
Last update
Oct 22, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 22, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01868555
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Jun 4, 2013
Start date
Dec 2007
Primary completion
Feb 2008
Completion
Feb 2008
Last update
Oct 22, 2015

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin degludec

Start the discussion